Research & Development

The success of ABS technologies is based in part on a continuing program of research and development. Our immediate goal is to utilize and enhance existing technologies. Also considered as a primary outcome in the ABS R&D effort is a series of testing procedures that will generate sufficient data to assure that all ABS products and services perform exactly as advertised. To this end, ABS has created a private-sector academic partnership in key science and technology areas. Our goal is to demonstrate the accuracy and reliability of ABS products and services.

• Chemical Synthesis Facility, Department of Chemistry, University of Arizona, Tucson, AZ
• Phoenix Biometrics, Inc. Tucson, AZ
• Lung Injury Lab, College of Medicine, University of Arizona Health Science Center, Tucson, AZ
• Material Sciences Lab, Clemson University, Clemson, South Carolina
• Genomic Microarray Core Laboratory, Cancer Center, University of Colorado Denver

All ABS work done in these facilities will adhere to Good Laboratory Practice (GLP) methodologies. This refers to a system of management controls for laboratories and research organizations to ensure the consistency and reliability of results.

Following GLP standards helps assure regulatory authorities that the data submitted are a true reflection of the results obtained during any ABS study and can therefore be relied upon when making risk and safety assessments

In addition, an Advisory Panel has been established drawing upon a range of scientific, medical, public-health and quality-assurance skill sets that will assist the ABS R&D program in establishing data at a level sufficient to maintain ABS as a leader in its market arena.

The Advisory Panel is under the direction of ABS Corporate Director, Charles A. Geoffrion, former Associate Vice President for Research at University of Arizona. The current membership includes those in the Advisory Committee.